{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:37:56Z","timestamp":1794710276047,"version":"4.9.1"},"update-to":[{"DOI":"10.1002\/14651858.cd004421.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T00:00:00Z","timestamp":1567382400000}}],"reference-count":128,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004421.pub3","type":"journal-article","created":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T16:05:31Z","timestamp":1567440331000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Taxanes for adjuvant treatment of early breast cancer"],"prefix":"10.1002","author":[{"given":"Melina L","family":"Willson","sequence":"first","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney; Systematic Reviews and Health Technology Assessments; Locked Bag 77 Sydney NSW Australia 1450"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda","family":"Burke","sequence":"additional","affiliation":[{"name":"Chris O'Brien Lifehouse; Department of Radiation Oncology; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Royal Perth Hospital; Department of Medical Oncology; Wellington St Perth WA Australia 6010"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davina","family":"Ghersi","sequence":"additional","affiliation":[{"name":"National Health and Medical Research Council; Research Policy and Translation; 16 Marcus Clarke Street Canberra ACT Australia 2601"},{"name":"The University of Sydney; Sydney Medical School; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K","family":"Nowak","sequence":"additional","affiliation":[{"name":"Sir Charles Gairdiner Hospital and University of Western Australia; Department of Medical Oncology; B Block, Hospital Avenue Nedlands Perth WA Australia 6099"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Wilcken","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney Medical School; Sydney Australia"},{"name":"Crown Princess Mary Cancer Centre; Medical Oncology; Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,2]]},"reference":[{"issue":"Suppl 16","key":"10.1002\/14651858.CD004421.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1200\/jco.2005.23.16_suppl.908","article-title":"Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with \u2265 4 involved lymph nodes: ADEBAR-Study","volume":"23","author":"Gauger","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD004421.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/bjc.2016.82","article-title":"Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study","volume":"114","author":"Janni","year":"2016","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0003|cit3","unstructured":"Janni W Harbeck N Sommer H Rack B Augustin D Jueckstock J Randomized phase III trial of fluorouracil\/epirubicin\/cyclophosphamide (FEC) versus epirubicin\/cyclophosphamide\/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study Author provided draft manuscript."},{"key":"10.1002\/14651858.CD004421.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1158\/0008-5472.SABCS-09-604","article-title":"Sequential treatment with epirubicin\/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study","volume":"69","author":"Janni","year":"2009","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/jco.2012.30.15_suppl.1081","article-title":"Sequential treatment with epirubicin\/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node-positive breast cancer patients: final survival analysis of the German ADEBAR phase III study","volume":"30","author":"Janni","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"PD07","DOI":"10.1158\/0008-5472.SABCS11-PD07-01","article-title":"Sequential treatment with epirubicin\/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study","volume":"71","author":"Janni","year":"2011","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0007|cit7","unstructured":"NCT00047099 Combination chemotherapy in treating women with breast cancer clinicaltrials.gov\/ct2\/show\/NCT00047099"},{"issue":"4","key":"10.1002\/14651858.CD004421.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000341384","article-title":"Toxicity analysis in the ADEBAR trial: sequential anthracycline-taxane therapy compared with FEC120 for the adjuvant treatment of high-risk breast cancer","volume":"7","author":"Schonherr","year":"2012","journal-title":"Breast Care"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.breast.2016.03.003","article-title":"Short term quality of life with epirubicin-fluorouracil-cyclophosphamide (FEC) and sequential\/cyclophosphamide-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - results from the prospective multi-center randomized ADEBAR trial","volume":"27","author":"Schwentner","year":"2016","journal-title":"The Breast"},{"issue":"1","key":"10.1002\/14651858.CD004421.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1470-2045(12)70525-9","article-title":"Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial","volume":"14","author":"Mackey","year":"2013","journal-title":"Lancet Oncology"},{"issue":"22","key":"10.1002\/14651858.CD004421.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","article-title":"Adjuvant docetaxel for node-positive breast cancer","volume":"352","author":"Martin","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 18","key":"10.1002\/14651858.CD004421.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"LBA519","DOI":"10.1200\/jco.2006.24.18_suppl.lba519","article-title":"Docetaxel given concurrently with or sequentially to anthracycline-based adjuvant therapy for patients with node-positive breast cancer, in comparison with non-taxane combination chemotherapy: first results of the BIG 2-98 trial at 5 years median follow-up","volume":"24","author":"Crown","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD004421.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jnci\/djm287","article-title":"Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial","volume":"100","author":"Francis","year":"2008","journal-title":"Journal of the National Cancer Institute"},{"issue":"12","key":"10.1002\/14651858.CD004421.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.ejca.2015.03.018","article-title":"Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer","volume":"51","author":"Sonnenblick","year":"2015","journal-title":"European Journal of Cancer"},{"issue":"3-4","key":"10.1002\/14651858.CD004421.pub3-BIB0015|cit15","first-page":"274","article-title":"Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer","volume":"78","author":"Boccardo","year":"2010","journal-title":"Oncology (United States)"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/jco.2013.31.15_suppl.1007","article-title":"Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101","volume":"31","author":"Shulman","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1002\/14651858.CD004421.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2013.53.7142","article-title":"Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance)","volume":"32","author":"Shulman","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"33","key":"10.1002\/14651858.CD004421.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO.2011.40.6405","article-title":"Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101","volume":"30","author":"Shulman","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD004421.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","article-title":"Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer","volume":"21","author":"Henderson","year":"March 2003","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD004421.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1200\/JCO.2010.32.7254","article-title":"Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer","volume":"29","author":"Coombes","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/jco.2010.28.15_suppl.536","article-title":"DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node-positive postmenopausal early breast cancer (EBC) patients","volume":"28","author":"Coombes","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0022|cit22","unstructured":"International Cancer Collaborative Group A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients Protocol only 1997"},{"issue":"16 Suppl 7","key":"10.1002\/14651858.CD004421.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"Abstract 512","DOI":"10.1200\/jco.2005.23.16_suppl.512","article-title":"E2197. Phase III AT vs. AC in the adjuvant treatment of node-positive and high-risk node-negative breast cancer","volume":"23","author":"Goldstein","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"25","key":"10.1002\/14651858.CD004421.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1200\/JCO.2008.16.7841","article-title":"Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197","volume":"26","author":"Goldstein","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/jco.2012.30.15_suppl.1021","article-title":"10-year update of E2197: phase III doxorubicin\/docetaxel (AT) versus doxorubicin\/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features","volume":"30","author":"Sparano","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD004421.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/jco.2005.23.16_suppl.513","article-title":"European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil","volume":"23","author":"Gianni","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD004421.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"8715","DOI":"10.1158\/1078-0432.CCR-05-0539","article-title":"Feasibility and tolerability of sequential doxorubicin\/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy","volume":"11","author":"Gianni","year":"2005","journal-title":"Clinical Cancer Research"},{"issue":"15","key":"10.1002\/14651858.CD004421.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2008.19.2567","article-title":"Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer","volume":"27","author":"Gianni","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD004421.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.critrevonc.2007.10.006","article-title":"Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial","volume":"66","author":"Nuzzo","year":"2008","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"4","key":"10.1002\/14651858.CD004421.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/annonc\/mdu564","article-title":"Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial","volume":"26","author":"Perrone","year":"2015","journal-title":"Annals of Oncology"},{"issue":"34","key":"10.1002\/14651858.CD004421.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1200\/JCO.2008.21.4577","article-title":"Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial","volume":"27","author":"Joensuu","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD004421.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer","volume":"354","author":"Joensuu","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0034|cit33","unstructured":"Martin M Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients Physician Data Query (PDQ) 2005"},{"issue":"20","key":"10.1002\/14651858.CD004421.pub3-BIB0033|cit34","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2012.46.9841","article-title":"Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results form the GEICAM\/2003-02 study","volume":"31","author":"Martin","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0036|cit35","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1200\/jco.2005.23.16_suppl.604","article-title":"Toxicity and health-related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805","volume":"23","author":"Martin","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0037|cit36","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1200\/jco.2004.22.90140.620","article-title":"Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer: an interim safety analysis of the GEICAM 9805 study","volume":"22","author":"Martin","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"23","key":"10.1002\/14651858.CD004421.pub3-BIB0038|cit37","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa0910320","article-title":"Adjuvant docetaxel for high-risk, node-negative breast cancer","volume":"363","author":"Martin","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD004421.pub3-BIB0035|cit38","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/annonc\/mdl135","article-title":"Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen","volume":"17","author":"Mart\u00edn","year":"2006","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD004421.pub3-BIB0040|cit39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10549-009-0663-z","article-title":"Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer","volume":"123","author":"Martin","year":"2010","journal-title":"Breast Cancer Research and Treatment"},{"issue":"11","key":"10.1002\/14651858.CD004421.pub3-BIB0041|cit40","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jnci\/djn151","article-title":"Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer","volume":"100","author":"Martin","year":"2008","journal-title":"Journal of the National Cancer Institute"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004421.pub3-BIB0039|cit41","first-page":"39","article-title":"Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial","volume":"94","author":"Mart\u00edn","year":"2005","journal-title":"Breast Cancer Research and Treatment"},{"issue":"Suppl 14","key":"10.1002\/14651858.CD004421.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1200\/jco.2004.22.90140.596","article-title":"Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial","volume":"22","author":"Rodriguez-Lescure","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0043|cit43","first-page":"1836","article-title":"Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study","volume":"20","author":"Rome","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD004421.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdr412","article-title":"A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study","volume":"23","author":"Vici","year":"2012","journal-title":"Annals of Oncology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD004421.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1200\/jco.2008.26.15_suppl.516","article-title":"Cyclophosphamide, epirubicin, and 5-fluorouracil versus epirubicin plus paclitaxel in node-positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest-Mammella Intergruppo Group","volume":"26","author":"Mastro","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD004421.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-015-3655-1","article-title":"5-fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase III randomized GONO-MIG5 trial","volume":"155","author":"Mastro","year":"2016","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0047|cit47","unstructured":"NCT02450058 Adjuvant FEC versus EP in breast cancer (MIG5) clinicaltrials.gov\/ct2\/show\/NCT02450058"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0048|cit48","first-page":"363","article-title":"Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study","volume":"19","author":"Participating Institutions to GONO-MIG 5 study","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD004421.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdi366","article-title":"Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group","volume":"16","author":"Fountzilas","year":"2005","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD004421.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10549-009-0468-0","article-title":"FEC versus sequential docetaxel followed by epirubicin\/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)","volume":"119","author":"Polyzos","year":"2010","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0051|cit51","unstructured":"NCT01204437 Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE-II) clinicaltrials.gov\/ct2\/show\/NCT01204437"},{"issue":"20","key":"10.1002\/14651858.CD004421.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1002\/cncr.29506","article-title":"A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)","volume":"121","author":"Minckwitz","year":"2015","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0053|cit53","unstructured":"Burnell M Levine M Chapman JA A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium 2006 53"},{"issue":"1","key":"10.1002\/14651858.CD004421.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2009.22.1077","article-title":"Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer","volume":"28","author":"Burnell","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 24","key":"10.1002\/14651858.CD004421.pub3-BIB0055|cit55","first-page":"P1","article-title":"A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis","volume":"72","author":"Burnell","year":"2012","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0056|cit56","unstructured":"Participating Organisations Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G-CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high-risk node negative stage 1-3A breast cancer Protocol only 2001"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0057|cit57","unstructured":"Burnell M Levine M Chapman JA A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium 2006 53"},{"issue":"1","key":"10.1002\/14651858.CD004421.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2009.22.1077","article-title":"Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer","volume":"28","author":"Burnell","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 24","key":"10.1002\/14651858.CD004421.pub3-BIB0059|cit59","first-page":"P1","article-title":"A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis","volume":"72","author":"Burnell","year":"2012","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0060|cit60","unstructured":"Participating Organisations Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G-CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high-risk node negative stage 1-3A breast cancer Protocol only"},{"issue":"16","key":"10.1002\/14651858.CD004421.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2005.10.517","article-title":"Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28","volume":"23","author":"Mamounas","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD004421.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1634\/theoncologist.2011-0442","article-title":"Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial","volume":"17","author":"Coudert","year":"2012","journal-title":"Oncologist"},{"issue":"7","key":"10.1002\/14651858.CD004421.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/annonc\/mdp561","article-title":"Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study","volume":"21","author":"Marino","year":"2010","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0065|cit64","unstructured":"Roche H Fumoleau P Spielmann M Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer San Antonio Breast Cancer Symposium 2004"},{"issue":"36","key":"10.1002\/14651858.CD004421.pub3-BIB0064|cit65","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","article-title":"Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial","volume":"24","author":"Roch\u00e9","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD004421.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1158\/0008-5472.SABCS-4101","article-title":"Final results of the RAPP-01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high-risk node negative and limited node positive (\u2264 3) breast cancer patients","volume":"69","author":"Brain","year":"2009","journal-title":"Cancer Research"},{"issue":"19","key":"10.1002\/14651858.CD004421.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.293.19.2367","article-title":"Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer","volume":"293","author":"Brain","year":"2005","journal-title":"Journal of the American Medical Asssociation"},{"issue":"Suppl 14","key":"10.1002\/14651858.CD004421.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1200\/jco.2004.22.90140.617","article-title":"Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high-risk node negative (pN0) and limited node positive (pN+<\/=3) breast cancer (BC) patients (pts): first analysis of toxicity","volume":"22","author":"Brain","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD004421.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4103\/0019-509X.104483","article-title":"Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node-positive breast cancer","volume":"49","author":"Roy","year":"2012","journal-title":"Indian Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD004421.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s12032-013-0457-3","article-title":"Sequential docetaxel as adjuvant chemotherapy for node-positive or\/and T3 or T4 breast cancer: clinical outcome (Mansoura University)","volume":"30","author":"Sakr","year":"2013","journal-title":"Medical Oncology"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"LBA520","DOI":"10.1200\/jco.2006.24.18_suppl.lba520","article-title":"Sequential epirubicin-docetaxel-CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial","volume":"24","author":"Bianco","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD004421.pub3-BIB0072|cit72","first-page":"viii77-viii88:","article-title":"Sequential epirubicin-docetaxel-CMF as adjuvant therapy for node-positive early stage breast cancer: updated results of the taxit216 randomized trial","volume":"19","author":"Cognetti","year":"2008","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0073|cit73","article-title":"Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial","volume-title":"Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial","author":"Forestieri","year":"2008"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0074|cit74","unstructured":"NCT00789581 A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN) clinicaltrials.gov\/ct2\/show\/NCT00789581"},{"issue":"3","key":"10.1002\/14651858.CD004421.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10549-017-4285-6","article-title":"TITAN: phase III study of doxorubicin\/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer","volume":"164","author":"Yardley","year":"2017","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0076|cit76","doi-asserted-by":"crossref","unstructured":"Yardley DA Hainsworth JD Harwin WN Goble SA Daniel BR Ackerman MA TITAN: ixabepilone versus weekly paclitaxel following doxorubicin\/cyclophosphamide (AC) adjuvant chemotherapy in triple-negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial Journal of Clinical Oncology 2011 1103","DOI":"10.1200\/jco.2011.29.15_suppl.1103"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1158\/0008-5472.SABCS12-P1-13-03","article-title":"Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01\/001); effects of treatment and characterisation of patterns of breast cancer relapse","volume":"72","author":"Bliss","year":"2012","journal-title":"Cancer Research"},{"issue":"9676","key":"10.1002\/14651858.CD004421.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S0140-6736(09)60740-6","article-title":"Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial","volume":"373","author":"Ellis","year":"2009","journal-title":"The Lancet"},{"issue":"Suppl 16","key":"10.1002\/14651858.CD004421.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/jco.2005.23.16_suppl.661","article-title":"Impact of quality of life (QL) during chemotherapy (CT) of FEC-T compared to FEC or E-CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT)","volume":"23","author":"Hopwood","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0080|cit80","unstructured":"Participating Organizations Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer Protocol only 2002"},{"issue":"8","key":"10.1002\/14651858.CD004421.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.2008.18.4028","article-title":"Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735","volume":"27","author":"Jones","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0082|cit82","first-page":"128","article-title":"Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1-3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC","volume":"20","author":"Jones","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"34","key":"10.1002\/14651858.CD004421.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","article-title":"Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer","volume":"24","author":"Jones","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD004421.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-011-1562-7","article-title":"Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control","volume":"128","author":"Albert","year":"2011","journal-title":"Breast Cancer Research and Treatment"},{"issue":"1","key":"10.1002\/14651858.CD004421.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12609-009-0001-9","article-title":"Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer","volume":"1","author":"Dang","year":"2009","journal-title":"Current Breast Cancer Reports"},{"issue":"2","key":"10.1002\/14651858.CD004421.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1008345432342","article-title":"Feasibility of docetaxel-containing regimens in the adjuvant treatment of breast cancer","volume":"11","author":"Leo","year":"2000","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD004421.pub3-BIB0087|cit87","first-page":"308","article-title":"High dose therapy for high risk (stage 3) breast cancer. Phase II trials of two treatment regimens cytoxan-etoposide-cisplatin and cytoxan-etoposide-cisplatin-taxol-carboplatin","volume":"46","author":"Dunphy","year":"1997","journal-title":"Breast Cancer Research and Treatment"},{"issue":"8","key":"10.1002\/14651858.CD004421.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1200\/JCO.2008.18.1024","article-title":"Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial","volume":"27","author":"Hugh","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD004421.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/sj.bjc.6603085","article-title":"Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer","volume":"94","author":"Kummel","year":"2006","journal-title":"British Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD004421.pub3-BIB0090|cit90","first-page":"1073","article-title":"Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial","volume":"8","author":"Buzdar","year":"2002","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0091|cit91","unstructured":"NCT02838225 DA versus DAC as postoperative adjuvant treatment for early-stage breast cancer clinicaltrials.gov\/ct2\/show\/NCT02838225"},{"issue":"13","key":"10.1002\/14651858.CD004421.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","article-title":"Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27","volume":"24","author":"Bear","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"10.1002\/14651858.CD004421.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2015.60.9271","article-title":"Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer","volume":"33","author":"Sparano","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1200\/jco.2011.29.15_suppl.1004","article-title":"First analysis of SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early breast cancer","volume":"29","author":"Budd","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"10.1002\/14651858.CD004421.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1200\/JCO.2006.08.9383","article-title":"Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group\/Intergroup Study 9623","volume":"25","author":"Moore","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0096|cit96","unstructured":"Mortimer JE A comparison of intensive sequential chemotherapy using doxorubicin plus paclitaxel plus cyclophosphamide with high dose chemotherapy and autologous hematopoietic progenitor cell support for primary breast cancer in women with 4-9 involved axillary lymph nodes, phase 3, Intergroup Protocol only 2001"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0097|cit97","unstructured":"Wildiers H A randomized phase II trial exploring feasibility of densification and optimal sequencing of postoperative adjuvant fluorouracil, epirubicin plus cyclophosphamide (FEC) and docetaxel chemotherapy in patients with high risk primary operable breast cancer Physician Data Query (PDQ) 2006"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1158\/0008-5472.SABCS11-P1-06-03","article-title":"Predictive value of HER2, topoisomerase-II (Topo-II) and tissue inhibitor of metalloproteinases (TIMP-1) for efficacy of taxane-based chemotherapy in intermediate risk breast cancer - results of the EC-Doc Trial","volume":"71","author":"Gluz","year":"2011","journal-title":"Cancer Research"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD004421.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1200\/jco.2008.26.15_suppl.515","article-title":"Interim results of Intergroup EC-Doc Trial: a randomized multicentre phase III trial comparing adjuvant CEF\/CMF to EC-Docetaxel in patients with 1-3 positive lymph nodes","volume":"26","author":"Nitz","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/0008-5472.SABCS-78","article-title":"Superiority of sequential docetaxel over standard FE100C in patients with intermediate risk breast cancer: survival results of the randomized intergroup phase III trial EC-Doc","volume":"69","author":"Nitz","year":"2008","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0101|cit101","doi-asserted-by":"crossref","unstructured":"Cardoso F Piccart-Gebhart MJ Rutgers EJ Litiere S Van't VL Viale G Standard anthracycline-based vs docetaxel-capecitabine in early breast cancer: results from the chemotherapy randomization (R-C) of EORTC 10041\/BIG3-04 MINDACT phase III trial Journal of Clinical Oncology; 2017 Annual meeting of the American Society of Clinical Oncology 2017 15 Suppl 1","DOI":"10.1200\/JCO.2017.35.15_suppl.516"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0102|cit102","first-page":"1073","article-title":"Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens","volume":"6","author":"Kader","year":"2013","journal-title":"OncoTargets and Therapy"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0103|cit103","unstructured":"Participating Organizations Phase 3 randomized study of adjuvant docetaxel and epirubicin versus adjuvant cyclophosphamide, epirubucin, and fluorouracil with or without trastuzumab in women with nonmetastatic adenocarcinoma of the breast with lymph node invasion Protocol only 2003"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1158\/0008-5472.SABCS-09-602","article-title":"Five-year analysis of the FNCLCC-PACS04 Trial: FEC100 vs ED75 for the adjuvant treatment of node positive breast cancer","volume":"69","author":"Roch\u00e9","year":"2009","journal-title":"Cancer Research"},{"issue":"36","key":"10.1002\/14651858.CD004421.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1200\/JCO.2009.23.0946","article-title":"Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial","volume":"27","author":"Spielmann","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0106|cit106","unstructured":"Participating Organizations Phase 2 randomized study of doxorubicin, cyclophosphamide, and paclitaxel vs cyclophosphamide, thiotepa, and carboplatin in patients with high-risk primary breast cancer Protocol only 2001"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0107|cit107","unstructured":"NCT01966471 A study of Kadcyla (trastuzumab emtansine) plus Perjeta (pertuzumab) following anthracyclines in comparison with Herceptin (trastuzumab) plus Perjeta and a taxane following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer clinicaltrials.gov\/show\/NCT01966471"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0108|cit108","unstructured":"NCT02549677 Epirubicin versus docetaxel plus cyclophosphamide in lymph node negative, ER-positive, Her2-negative breast cancer (ELEGANT) clinicaltrials.gov\/ct2\/show\/NCT02549677"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0109|cit109","first-page":"140","article-title":"Prospective evaluation of prognostic factors uPA\/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 x FEC versus 3 x FEC\/3 x docetaxel","volume":"11","author":"Kantelhardt","year":"2011","journal-title":"BioMed Central"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0110|cit110","unstructured":"Breast cancer in Australia: an overview Australian Institute of Health and Welfare & Cancer Australia. Case series no. 71. Canberra: Cat no CAN 67, October 2012"},{"issue":"8","key":"10.1002\/14651858.CD004421.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1200\/JCO.1999.17.8.2355","article-title":"Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer","volume":"17","author":"Bishop","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD004421.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1002\/cncr.21886","article-title":"Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients","volume":"106","author":"Bria","year":"2006","journal-title":"Cancer"},{"issue":"8","key":"10.1002\/14651858.CD004421.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group","volume":"17","author":"Chan","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD004421.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(02)00927-0","article-title":"Chemotherapy for metastatic breast cancer - report of a European expert panel","volume":"3","author":"Crown","year":"2002","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.","volume":"365","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"International Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD004421.pub3-BIB0117|cit117","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003366","article-title":"Taxane containing regimens for metastatic breast cancer","author":"Ghersi","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0118|cit118","unstructured":"GRADEproGDT: GRADEpro Guideline Development Tool [software] McMaster University, 2015 (developed by Evidence Prime, Inc). Available from www.gradepro.org"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0119|cit119","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer","volume":"354","author":"Joensuu","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0121|cit121","unstructured":"National Comprehensive Cancer Network Practice Guidelines in Oncology: Breast Cancer; Version 2, 2007 www.nccn.org\/professionals\/physician_gls\/PDF\/breast.pdf (accessed 30 April 2007)"},{"issue":"24","key":"10.1002\/14651858.CD004421.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"11","key":"10.1002\/14651858.CD004421.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"e26946","DOI":"10.1371\/journal.pone.0026946","article-title":"Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients","volume":"6","author":"Qin","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0124|cit124","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0125|cit125","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glaziou P Chapter 12. Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD004421.pub3-BIB0126|cit126","first-page":"16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Methodology"},{"issue":"1","key":"10.1002\/14651858.CD004421.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jama.1991.03470010097038","article-title":"Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials","volume":"266","author":"Yusuf","year":"1991","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD004421.pub3-BIB0128|cit128","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004421.pub2","article-title":"Taxanes for adjuvant treatment of early breast cancer","author":"Ferguson","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD004421.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T05:17:43Z","timestamp":1664255863000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD004421.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Breast Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,9,2]]},"references-count":128,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004421.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,2]]}}}